Clinical Trials, Industry, Research and Development, Vaccines
June 16, 2021
Via: Pharma TimesThe study, co-authored by Seqirus, was conducted as part of a Phase III clinical trial of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK. The co-administration sub-study enrolled a total of 431 volunteers, all of whom had received a flu vaccine […]
Cell and Gene Therapy, Industry
June 15, 2021
Via: EPM MagazineThe parliament advocated for an increase in the number of NUB inquiries that can take place each year. NUB inquiries are used by hospitals to gain short term reimbursement for innovative treatment and diagnostic methods, supplementing the standard Diagnosis Related […]
Cell and Gene Therapy, Industry
June 15, 2021
Via: Pharma TimesThe Phase III STAR study enrolled 169 adult males with a genetically confirmed diagnosis of choroideremia. It evaluated the safety and efficacy of a single subretinal injection of the investigational gene therapy. The primary endpoint was the proportion of patients […]
June 14, 2021
Via: Genetic Engineering and Biotechnology NewsThe good news about vaccines and variants continues to roll in. Last week, a study reported that Johnson & Johnson’s COVID-19 vaccine protected against all of the SARS-CoV-2 variants of concern. Now, Pfizer’s COVID-19 vaccine has been shown to protect […]
June 11, 2021
Via: Medical NewsThe National Comprehensive Cancer Network (NCCN) today announced the publication of new guidance on COVID-19 vaccines for people with cancer, intended to clear up confusion for patients and caregivers. The new four-page patient guide is based on the latest expert […]
June 11, 2021
Via: PharmaphorumThat will hold back the biotech’s Covaxin shot by several months, and the delay put pressure on Ocugen’s share price, which fell more than 25% after the announcement. The Philadelphia-based company said it had taken the decision to go down […]
June 10, 2021
Via: Medical NewsVaccines are mostly synonymous with needles, an efficient and effective way to provide immunity to myriad infections. As COVID-19 vaccination efforts roll out across the U.S. and the world, some experts believe that a vaccine administered through the nose could […]
June 10, 2021
Via: PharmaphorumThe scientists examined real-world public health data from all individuals in Scotland who received either the AZ or Pfizer/BioNTech vaccines up until 14 April and found a possible association between the AZ shot and an autoimmune disorder called idiopathic thrombocytopenic […]
Cell and Gene Therapy, Industry
June 9, 2021
Via: Biopharma DiveBeigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several […]
June 8, 2021
Via: EPM MagazineCyGenica raised the money in a seed fund investment round led by global venture capital investor SOSV. CyGenica will use the funding to accelerate the validation of its technology which is designed to enable safe, targeted and affordable intercellular drug […]
Cell and Gene Therapy, Industry
June 7, 2021
Via: Biopharma DiveThe approvals of Roche’s Luxturna (2017) for inherited retinal disease and Novartis’ Zolgensma (2019) for spinal muscular atrophy are indicative of a resurgence in the gene therapy field after a decline due to the death of a patient in 1999. […]
Cell and Gene Therapy, Industry, News, Pharma
June 7, 2021
Via: Pharma TimesThis includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers. Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials, and will also be used to […]
Copyright © 2021. All rights reserved
